FMFederico Mazzotti

Federico Mazzotti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Federico Mazzotti has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The impact of colectomy and restorative procedure on pouch function after ileo-pouch-anal anastomosis in ulcerative colitis. The icon fun study on behalf of the Italian Society of Colon and Rectal Surgery (SICCR) Inflammatory Bowel Diseases committee

    by Michela Mineccia, Alessandro Ferrero, Matteo Rottoli, Antonino Spinelli, Luigi Sofo, Giampaolo Ugolini, Giuliano Barugola, Giacomo Ruffo, Andrea Braini, Gaetano Luglio, et al.


  • Frailty assessment can predict textbook outcomes in senior adults after minimally invasive colorectal cancer surgery

    by Giovanni Taffurelli, Isacco Montroni, Federico Ghignone, Davide Zattoni, Anna Garutti, Francesca Di Candido, Federico Mazzotti, Giacomo Frascaroli, Stefano Tamberi, Giampaolo Ugolini


  • Years of Life Lost for Older Patients After Colorectal Cancer Diagnosis

    by Federico Mazzotti, Alessandro Cucchetti, Yvette H. M. Claassen, Amanda C. R. K. Bos, Esther Bastiaannet, Giorgio Ercolani, Jan Willem T. Dekker

    Background: An aging population combined with an increased colorectal cancer (CRC) incidence in the older population will increase its prevalence in the elderly, questioning how many years of life are lost (YLLs) in these patients.Patients and methods: Data from 32,568 Dutch CRC patients ≥ 80 years were used to estimate the number of YLLs after diagnosis, using a reference age‐, sex‐ and year‐of‐onset‐matched cohort derived from national life tables. YLLs were additionally adjusted by comorbidities. Number needed to treat (NNT) was used as measure of surgical effect size.Results: Surgery was applied in 74.9% of patients leading to 1.3 YLLs, being superior in 86.1% of cases with respect to alternative therapies (YLLs 4.8 years) and resulting in a number of two patients needed to operate to achieve one positive outcome. YLLs and NNTs depended on CRC stage, patient’ age and comorbidities. For Stage I–II patients in the best clinical conditions (80–85 years without comorbidities), YLLs increased up to 4.1 years after surgery and up to 8.8 years without surgery (NNT 3). For Stage III patients, the NNT of surgery varied between 2 when they were in the best clinical conditions and 4 when they were older with high comorbidities. In Stage IV patients, the NNT ranged between 6 and 31.Conclusions: YLLs represents a novel approach to evaluate CRC prognosis. Stage I–III surgical patients can have a life expectancy similar to that of general population, being the NNT of surgery reasonably small compared with alternatives. Personalized comorbidity data are needed to confirm present findings.


  • Open Access

    Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials

    by Alessandro Cucchetti, Fabio Piscaglia, Antonio Daniele Pinna, Benjamin Djulbegovic, Federico Mazzotti, Luigi Bolondi

    Aim/Background: After the introduction of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC), different studies tried to evaluate whether other systemic therapies can improve survival. To provide a comprehensive indirect treatment comparison of efficacy and safety of novel drugs, a network meta-analysis (NMA) of phase III randomized controlled trials was performed. Methods: After pertinent literature search up to November 1, 2016, 6 studies were eligible for the analysis including 4,812 individual patients with advanced HCC: 2,454 received sorafenib, 577 received brivanib, 530 received sunitinib, 514 received linifanib, 358 received sorafenib + erlotinib and 379 received placebo. Frequentist NMA was used to compare treatments within a single analytical framework. Results: NMA showed that sorafenib alone, regardless of combination with erlotinib, and linifanib provide a significant survival advantage over placebo (p < 0.05) but without any significant difference between each other. Conversely, all regimens significantly ameliorate progression-free survival versus placebo (p < 0.05). The rank order of efficacy was: sorafenib ± erlotinib, linifanib, brivanib, sunitinib, and placebo. Sorafenib ± erlotinib was the regimen with the fewest number of adverse events that required discontinuation of treatment, whereas linifanib and brivanib resulted in the most adverse events. The risk-benefit summary identified one cluster of therapies with a similar balance between efficacy and safety which included sorafenib alone or in combination with erlotinib, having, at the same time, the highest efficacy and safety. Conclusions: Sorafenib remains the best systemic treatment for advanced HCC; linifanib also resulted in survival advantages over placebo but with a lower safety profile.


  • Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome

    by Alessandro Cucchetti, Matteo Cescon, Antonio Colecchia, Flavia Neri, Alberta Cappelli, Matteo Ravaioli, Federico Mazzotti, Giorgio Ercolani, Davide Festi, Antonio Daniele Pinna

    Purpose Liver stiffness (LS) has been shown to be of use in chronic liver disease patients but its utility in surgical judgment still needs to be proven. A decision-making approach was applied to evaluate whether LS measurement before surgery of hepatocellular carcinoma (HCC) can be useful in avoiding post-hepatectomy liver failure (PHLF). Materials and Methods Decision curve analysis (DCA) was applied to 202 HCC patients (2008 – 14) with LS measurement prior to hepatectomy to verify whether the occurrence of PHLF grades B/C should be reduced through a decision-making approach with LS. Results Within 90 days of surgery, 4 patients died (2 %) and grades B/C PHLF occurred in 29.7 % of cases. Ascites and/or pleural effusion, treatable with medical therapy, were the most frequent complications. DCA showed that using the “expected utility theory” LS measurement can reduce up to 39 % of cases of PHLF without the exclusion of any patient from surgery that duly undergoes an uncomplicated postoperative course. LS measurement does not add any information to normal clinical judgment for patients with a low (< 10 %) risk of PHLF. Conclusion LS measurement can determine a reduction of PHLF under “expected utility theory” fulfilment. However, the degree of PHLF can be minor and “risk seeking” individuals can accept such a risk on the basis of surgical benefits. Ziel Der Einsatz der Lebersteifigkeit (LS) hat sich bei Patienten mit chronischen Lebererkrankungen als hilfreich erwiesen, aber dessen Nutzen bei der chirurgischen Entscheidung muss noch überprüft werden. Ein Entscheidungsfindungsansatz wurde angewandt, um festzustellen, ob präoperative LS-Bestimmungen beim hepatozellulärem Karzinom (HCC) von Nutzen sind, um das postoperative Leberversagen (posthepatectomy liver failure, PHLF) zu verhindern. Material und Methoden Bei 202 HCC-Patienten mit LS-Bestimmung vor Leberresektion (2008 – 14) wurde eine „Decision Curve Analysis“ (DCA) durchgeführt, um zu überprüfen, ob das Auftreten eines PHLF-Grad B/C durch die Entscheidungsfindung mittels LS verringert werden kann. Ergebnisse Innerhalb von 90 Tagen nach Leberresektion starben 4 Patienten (2 %) und Grad B/C PHLF trat in 29,7 % der Fälle auf. Aszites und / oder Pleuraergüsse, die medikamentös behandelbar sind, waren die häufigsten Komplikationen. Die DCA zeigte, dass die Anwendung der LS-Bestimmung mittels „Expected Utility Theory“ die Fälle mit PHLF um bis zu 39 % reduzieren kann, ohne irgendeinen Patienten mit ordnungsgemäßem unkomplizierten postoperativen Verlauf von der Operation auszuschließen. Die LS-Bestimmung liefert keine zusätzliche Information für die normale klinische Entscheidung über Patienten mit niedrigem PHLF-Risiko (< 10 %). Schlussfolgerung Die LS-Bestimmung kann zu einer Reduktion des PHLF bei Durchführung der „Expected Utility Theory“ führen. Allerdings kann der Grad des PHLF gering sein, und „risikobereite“ Personen können ein solches Risiko im Hinblick auf den chirurgischen Nutzen akzeptieren.


  • Top Cited Papers

    Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?

    by Matteo Renzulli, Stefano Brocchi, Alessandro Cucchetti, Federico Mazzotti, Cristina Mosconi, Camilla Sportoletti, Giovanni Brandi, Antonio Daniele Pinna, Rita Golfieri

    Some “worrisome” imaging features, such as nonsmooth tumor margins, peritumoral enhancement, two-trait predictor of venous invasion (“internal arteries” and “hypoattenuating halos”), and large tumor size were used to significantly predict the presence of microvascular invasion in hepatocellular carcinoma. PurposeTo determine the accuracy of imaging features, such as tumor dimension, multinodularity, nonsmooth tumor margins, peritumoral enhancement, and radiogenomic algorithm based on the association between imaging features (internal arteries and hypoattenuating halos) and gene expression that the authors called two-trait predictor of venous invasion (TTPVI), in the prediction of microvascular invasion (MVI) in hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. One hundred twenty-five patients (median age, 63 years; interquartile range, 53–71 years) with a diagnosis of HCC and indications for hepatic resection were included. Two observers independently reviewed radiologic images to evaluate the following features for MVI: maximum diameter, number of lesions, tumor margins, TTPVI, and peritumoral enhancement. Interobserver agreement was checked, and diagnostic accuracy...


  • Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma

    by Alessandro Cucchetti, Matteo Cescon, Rita Golfieri, Fabio Piscaglia, Matteo Renzulli, Flavia Neri, Alberta Cappelli, Federico Mazzotti, Cristina Mosconi, Antonio Colecchia, et al.


  • Cure Model Survival Analysis After Hepatic Resection for Colorectal Liver Metastases

    by Alessando Cucchetti, Alessandro Ferrero, Matteo Cescon, Matteo Donadon, Nadia Russolillo, Giorgio Ercolani, Giacomo Stacchini, Federico Mazzotti, Guido Torzilli, Antonio Daniele Pinna

    Statistical cure is achieved when a patient population has the same mortality as cancer-free individuals; however, data regarding the probability of cure after hepatectomy of colorectal liver metastases (CLM) have never been provided. We aimed to assess the probability of being statistically cured from CLM by hepatic resection. Data from 1,012 consecutive patients undergoing curative resection for CLM (2001–2012) were used to fit a nonmixture cure model to compare mortality after surgery to that expected for the general population matched by sex and age. The 5- and 10-year disease-free survival was 18.9 and 15.8 %; the corresponding overall survival was 44.3 and 32.7 %. In the entire study population, the probability of being cured from CLM was 20 % (95 % confidence interval 16.5–23.5). After the first year, the mortality excess of resected patients, in comparison to the general population, starts to decline until it approaches zero 6 years after surgery. After 6.48 years, patients alive without tumor recurrence can be considered cured with 99 % certainty. Multivariate analysis showed that cure probabilities range from 40.9 % in patients with node-negative primary tumors and metachronous presentation of a single lesion <3 cm, to 1.5 % in patients with node positivity, and synchronous presentation of multiple, large CLMs. A model for the calculation of a cure fraction for each possible clinical scenario is provided. Using a cure model, the present results indicate that statistical cure of CLM is possible after hepatectomy; providing this information can help clinicians give more precise answer to patients’ questions.


    • 1 June 2014
      • Vol. 80  (6) , 645-654

    Assessment of perioperative transfusion requirement for cirrhotic patients undergoing elective hepatectomy

    by A. Cucchetti, A. Siniscalchi, M. Cescon, F. Mazzotti, G. Ercolani, M. Ravaioli, S. Faenza, A. D. Pinna

    Background. The possibility of outlining a risk profile for perioperative blood transfusion of cirrhotic patients submitted to hepatic resection can help to rationalize transfusion policy Methods. Data from 323 hepatic resections, performed in cirrhotic patients, were reviewed. Bootstrap and a leave-one-out logistic regressions were applied to test the accuracy of available risk scores for pen-operative transfusion identified from PubMed search of the last 20 years, to refine them, and to provide internal validation for present results. Results. One-hundred-six patients (32.8%) required blood transfusions during either intra- and/or postoperative. The predictive accuracy of three identified risk scores was poor with the area under receiver operating characteristics (AUROC) curves <0.70 in all cases. Tumor diameter, hemoglobin and presence of coronary artery disease were confirmed, in the present cohort, as predictors of blood transfusion together with serum albumin and bilirubin. The leave-one-out logistic regression results in an AUROC of 0.80, and of 0.79 for internal validation, significantly higher than that of the three scores tested (P<0.001). A Maximal Surgical Blood Order Schedule stratification was proposed. Conclusion. The risk profile for transfusion of Cirrhotic patients undergoing hepatectomy can be better assessed with a model that combines already known clinical factors and hepatic function indexes.

  • The use of the Hirsch index in benchmarking hepatic surgery research

    by Alessandro Cucchetti, Federico Mazzotti, Sara Pellegrini, Matteo Cescon, Lorenzo Maroni, Giorgio Ercolani, Antonio Daniele Pinna